Improved meningococcal polysaccharide conjugate vaccine

Details Improved meningococcal polysaccharide conjugate vaccine Improved meningococcal polysaccharide conjugate vaccine

A - Human Necessities

61

K

A61K 39/095 (2006.01) A61K 39/08 (2006.01) A61K 39/108 (2006.01) A61K 39/385 (2006.01) A61K 39/40 (2006.01) C07K 16/12 (2006.01) A61K 38/00 (2006.01)

Patent

CA 2071811

Neisseria meningitidis group B polysaccharide (GBMP) modified by having sialic acid residue N-acetyl groups replaced by N-aryl groups exhibits enhanced immuno response thereto. In addition, induction of antibodies which cross-react with un- modified group B meningococcal and E. coli K1 capsular polysaccharide and other tissue cells having a common epitope is mini- mized. Conjugation of the modified polysaccharides with a physiologically acceptable protein such as tetanus toxoid induces the production of specific protective antibodies with negligible levels of GBMP- cross reactive antibodies, to thereby afford protection against infections caused by group B meningococci and E. coli K1.

Affiliated with

Also associated with

Rating

Improved meningococcal polysaccharide conjugate vaccine does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Improved meningococcal polysaccharide conjugate vaccine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Improved meningococcal polysaccharide conjugate vaccine will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1519447